“Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBP&agr; (CCAAT/enhancer binding protein-&agr;), and C/EBP&egr;. Our results concluded the usefulness of belinostat, as an epigenetic drug, for antileukemia and differentiation therapy.”